LRRK2 and Parkinson disease: Also, by looking at subsets of PD patients, our data suggest that some of the parameters tested such as Rab8a, TSG101, pS910-LRRK2, pT72-Rab8a are altered in specific patients groups such as de novo compare to non de novo or patients with MCI compared to those without, indicating a potential to stratify different patients groups.